国家自然科学基金面上项目：肠菌产物丁酸盐诱导的肥大细胞通过外泌体穿梭LINC-01028调控DRG神经元TRPV1参与内脏高敏感的机制研究（82270571）(2023.01-2026.12)

国家自然科学基金青年基金项目：益生菌VSL#3对应激诱发的内脏高敏感大鼠中肥大细胞-PAR2-TRPV1通路的调控机制（81300273）(2014.01-2016.12)

辽宁省科学技术基金面上项目：益生菌VSL#3调控脊髓背角突触可塑性在内脏高敏感中的作用机制（20170541052）

中国医科大学“扬帆计划”等课题：SCFA通过肥大细胞外泌体miRNA-124和miRNA-21介导DRG神经元参与内脏高敏感的调控机制

发表文章:

1. Dai C, Huang YH, Jiang M. Combination therapy in inflammatory bowel disease: Current evidence and perspectives. Int Immunopharmacol. 2023;114:109545.

2. Dai C, Huang YH, Jiang M. Post-COVID-19 irritable bowel syndrome. Gut. 2023:329714.

3. Dai C, Jiang M, Huang YH. Efficacy of Mesalamine in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2023:S1542-3565(23)00229-X.

4. Dai C, Huang YH. Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2023;29(4):e14.

5. Dai C, Huang YH. Venous Thromboembolism Following Discharge from Hospital Among Patients Admitted for Inflammatory Bowel Diseases. J Crohns Colitis. 2023;17(2):305.

6. Dai C, Dong ZY, Wang YN, Huang YH, Jiang M. Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents. Rev Esp Enferm Dig. 2023;116.

7. Dai C, Jiang M, Huang YH. Neutrophil-to-Lymphocyte Ratio for the Diagnosis and Monitoring of Inflammatory Bowel Disease. Dig Dis Sci. 2023;68(2):703-704.

8. Dai C, Huang YH. Successful treatment of Crohn's disease, aseptic liver abscess and psoriasis with ustekinumab. Rev Esp Enferm Dig. 2023;115(3):155-156.

9. Dai C, Huang YH. Dose-Intensified Infliximab Rescue Therapy on Short-term Colectomy Rates in Patients With Severe Ulcerative Colitis. Dis Colon Rectum. 2023;66(3):e127.

10. Dai C, Huang YH. Letter: pancreatic involvement in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;56(2):370.

11. Dai C, Jiang M, Huang YH. Appendectomy and Future Risk of Microscopic Colitis: Correlation or Causation? Clin Gastroenterol Hepatol. 2022:S1542-3565(22)00713-3.

12. Dai C, Huang YH. The Role of Appendicectomy in Ulcerative Colitis: True or Coincidental Association? Inflamm Bowel Dis. 2022;28(11):e149.

13. Dai C, Jiang M, Huang YH. Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022;20(6):1416.

14. Dai C, Jiang M, Huang YH. Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy. Dig Dis Sci. 2022;67(11):5353-5354.

15. Dai C, Huang YH, Jiang M. Successful Treatment of Ulcerative Colitis, Rectovaginal Fistula, and Skin Erythema Nodule With Adalimumab. Inflamm Bowel Dis. 2022;28(3):e36-e37.

16. Dai C, Huang YH. Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery. Dig Dis Sci. 2022;67(4):1421-1422.

17. Dai C, Jiang M, Huang YH. COVID-19 Vaccination in Patients with Inflammatory Bowel Disease: A Survey from China. Dig Dis Sci. 2022;67(7):3468-3470.

18. Dai C, Jiang M, Huang YH. Anti-TNF Withdrawal in Inflammatory Bowel Disease With Endoscopic Healing and the Risk of Relapse. Clin Gastroenterol Hepatol. 2022:S1542-3565(22)00914-4.

19. Dai C, Liu WX. Refractory Immune Checkpoint Inhibitor-induced Colitis Improved by Fecal Microbiota Transplantation: A Case Report. Inflamm Bowel Dis. 2022;28(3):e43-e44.

20. Dai C, Dong ZY, Wang YN, Huang YH, Jiang M. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2022;114.

21. Dai C, Huang YH. Letter to the Editor on "Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease Patients During the SARS- CoV-2 Pandemic". Dig Dis Sci. 2022;67(1):348-349.

22. Dai C, Wang YN, Tian WN, Huang YH, Jiang M. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor- induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis. Int Immunopharmacol. 2022;112:109269.

23. Dai C, Wen Y. A rare case of an intestinal ulcer: AIDS and amebic colitis in a homosexual man with ulcerative colitis. Rev Esp Enferm Dig. 2022;114(12):745.

24. Dai C, Huang YH. A Rare Manifestation of IgG4-Related Disease and Concurrent Idiopathic Hypereosinophilic Syndrome as Extensive Gastrointestinal Lesions: A Case Report. Inflamm Bowel Dis. 2022;28(6):e82-e83.

25. Tian WN, Huang YH, Dai C. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: A Survey From China. Inflamm Bowel Dis. 2022;28(10):e134-e136.

26. Tian WN, Huang YH, Jiang M, Dai C. Self-reported Treatment Goals in Chinese Patients with Inflammatory Bowel Disease During the Coronavirus Disease 2019 Pandemic. Turk J Gastroenterol. 2022;33(7):554-564.

27. Dai C, Huang YH. Biological Therapy in Chronic Antibiotic Refractory Pouchitis. J Clin Gastroenterol. 2021;55(10):911.

28. Dai C, Jiang M, Huang YH. Association Between Statin Use and Inflammatory Bowel Diseases. J Crohns Colitis. 2021;15(7):1246.

29. Dai C, Huang YH, Jiang M. Two Types of Fecal Tests in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021;19(1):209.

30. Dai C, Jiang M, Huang YH. Anti-Tubercular Therapy on the Long-Term Disease Course of Patients with Crohn's disease. J Crohns Colitis. 2021;15(1):169.

31. Dai C, Jiang M, Huang YH. The Association Between Serum Infliximab Concentrations and Clinical Outcomes in Fistulizing Crohn's Disease. Am J Gastroenterol. 2021;116(12):2481-2482.

32. Dai C, Jiang M, Huang YH. Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(12):e156.

33. Dai C, Jiang M, Huang YH. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis. J Gastroenterol Hepatol. 2021 ;36(7):2024-2025.

34. Dai C, Jiang M, Huang YH. The Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With COVID-19. Gastroenterology. 2021 ;161(5):1722.

35. Dai C, Jiang M. Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease. Dig Dis Sci. 2021 Mar;66(3):919-920. 

36. Zhao HN, Jiang M, Sun MJ, Dai C. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis. Saudi J Gastroenterol. 2021;27(4):191-200.

37. Xiang BJ, Huang YH, Dai C. A Rare Autoinflammatory Syndrome Involving Acute Severe Ulcerative Colitis Combined With Iritis. Inflamm Bowel Dis. 2021;27(7):e83-e86.

38. Xiang B, Dong Z, Dai C. The diagnostic and predictive value of fecal calprotectin and capsule endoscopy for small-bowel Crohn's disease: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2021;113(3):193-201.

39. Xiang BJ, Jiang M, Sun MJ, Dai C. Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Visc Med. 2021;37(5):338-348.

40. Dong ZY, Xiang BJ, Jiang M, Sun MJ, Dai C. The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021;55(1):67-76.

41. Dai C, Jiang M. Statin Use and the Overall Survival in Patients Diagnosed With Pancreatic Cancer. Pancreas. 2020;49(2):e19.

42. Dai C, Jiang M, Sun MJ. Acute Venous Thromboembolism Risk in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020;18(13):3058-3059.

43. Dai C, Huang YH, Yu JH. Urgent Versus Standard Colonscopy for Management of Acute Lower Gastrointestinal Bleeding. J Clin Gastroenterol. 2020;54(6):577.

44. Dai C, Jiang M. Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease? Am J Gastroenterol. 2020;115(2):303-304.

45. Dai C, Jiang M, Sun MJ, Cao Q. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020 ;54(6):545-553.

46. Dai C, Jiang M, Sun MJ. Disease Duration and the Risk of Treatment Failure in Biologic-Treated Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2020;26(3):e16.

47. Dai C, Jiang M, Sun MJ. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. Clin Gastroenterol Hepatol. 2020 ;18(1):262.

48. Dai C, Cao Q, Jiang M. Risk of Venous Thromboembolism After Hospital Discharge in Patients with Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2020;26(5):e43.

49. Dai C, Huang YH, Jiang M, Sun MJ. Nonclostridium difficile enteric infection and the risk of developing inflammatory bowel disease: A systematic review and meta-analysis. Saudi J Gastroenterol. 2020;26(6):299–305.

50. Tian WN, Huang YH, Dai C. The Effect of the COVID-19 Pandemic on the Medical Mode of Patients With Inflammatory Bowel Disease in China. Inflamm Bowel Dis. 2020;26(10):e116-e117.

51. Xiang B, Lv X, Dai C. Unusual case of pancreas disease involving parotid gland and submandibular gland. Intern Med J. 2020;50(7):888-889.

52. Li YJ, Li J, Dai C. The Role of Intestinal Microbiota and Mast Cell in a Rat Model of Visceral Hypersensitivity. J Neurogastroenterol Motil. 2020;26(4):529-538.

53. Dai C, Cao Q, Jiang M. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients. J Clin Gastroenterol. 2019; 53: 314.

54. Dai C, Jiang M, Huang YH. Effect of Accelerated Infliximab Induction on Outcomes of Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019.

55. Dai C, Jiang M, Huang YH. Appendectomy for Therapy-refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation. J Crohns Colitis. 2019; 13: 538.

56. Dai C, Jiang M, Huang YH. Risk Factors Associated With Clostridium difficile Infection in Inflammatory Bowel Disease. J Crohns Colitis. 2019; 13: 395.

57. Dai C, Jiang M, Sun MJ. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis. Dig Dis Sci. 2019.

58. Dai C, Jiang M, Sun MJ. The Effect of Smoking on the Risk of Pouchitis in Ulcerative Colitis Patients With Ileal Pouch-anal Anastomosis. Inflamm Bowel Dis. 2019; 25: e42.

59. Dai C, Jiang M, Sun MJ. Prediagnostic Serum Vitamin D Levels and the Risk of Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2019; 25: e6.

60. Dai C, Jiang M, Sun MJ. The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease. J Clin Gastroenterol. 2019; 53: 155.

61. Dai C, Jiang M, Sun MJ. Mesalazine in the Treatment of Symptomatic Uncomplicated Diverticular Disease. J Clin Gastroenterol. 2019; 53: 77-8.

62. Dai C, Jiang M, Sun MJ. Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn's disease. Clin Gastroenterol Hepatol. 2019.

63. Dai C, Jiang M, Sun MJ, Cao Q. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019.

64. Dai C, Jiang M, Yu JH. Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019.

65. Li YJ, Dai C, Jiang M. Mechanisms of Probiotic VSL#3 in a Rat Model of Visceral Hypersensitivity Involves the Mast Cell-PAR2-TRPV1 Pathway. Dig Dis Sci. 2019; 64: 1182-92.

66. Dai C, Jiang M, Huang YH. The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life. Inflamm Bowel Dis. 2019; 25: e61.

67. Dai C, Jiang M, Sun MJ. Oral Nano Vitamin D Supplementation and Disease Activity in Ulcerative Colitis. J Clin Gastroenterol. 2019.

68. Dai C, Jiang M, Sun MJ. Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than IBD. Aliment Pharmacol Ther. 2019; 50: 834-5.

69. Dai C, Jiang M. Comment on: Prospective cohort study of appendicectomy for treatment of therapy-refractory ulcerative colitis. Br J Surg. 2019;106(12):1705-1706.

70. Cao Q, Huang YH, Jiang M, Dai C. The prevalence and risk factors of psychological disorders, malnutrition and quality of life in IBD patients. Scand J Gastroenterol. 2019;54(12):1458-1466.

71. Dai C, Jiang M, Sun MJ, et al. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. J Gastroenterol Hepatol 2018.

72. Dai C, Jiang M, Sun MJ. Continued Use of Antiplatelet Agent May Increase the Risk of Delayed Bleeding After Endoscopic Submucosal Dissection. Dig Dis Sci 2018.

73. Dai C, Jiang M, Sun MJ. The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease. J Clin Gastroenterol 2018.

74. Dai C, Jiang M, Sun MJ. Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology 2018;154:256.

75. Dai C, Jiang M, Cao Q. Association between Depression and More Aggressive Inflammatory Bowel Disease. Am J Gastroenterol 2018.

76. Dai C, Cao Q, Sun MJ. Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium difficile Infection. Inflamm Bowel Dis 2018;24:662.

77. Dai C, Cao Q, Jiang M, et al. Serum Immunoglobulin G4 in Discriminating Autoimmune Pancreatitis From Pancreatic Cancer: A Diagnostic Meta-analysis. Pancreas 2018.

78. Dai C, Jiang M, Sun MJ. Association Between Proton Pump Inhibitor Use and Risk of Stroke. Gastroenterology. 2018 Sep;155(3):932-933.

79. Dai C, Jiang M, Sun MJ. The Association Between Consumption of Sweetened Beverages and the Risk of Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1681-1682.

80. Dai C, Jiang M, Sun MJ, Cao Q. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta- analysis. J Gastroenterol Hepatol. 2018 May;33(5):990-997.

81. Dai C, Jiang M, Sun MJ. Fecal Calprotectin in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci 2017.

82. Dai C, Jiang M, Sun MJ. Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease. J Crohns Colitis 2017;11:901.

83. Dai C, Jiang M, Cao Q. Steroid and the risk of venous thromboembolic events in inflammatory bowel disease. J Crohns Colitis 2017.

84. Dai C, Jiang M, Cao Q. Proton-Pump Inhibitor use and the risk of Ischaemic Stroke. J Intern Med 2017.

85. Dai C, Cao Q, Jiang M. Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. Aliment Pharmacol Ther 2017;46:1025-1026.

86. Dai C, Cao Q, Jiang M. Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population. Am J Gastroenterol 2017;112:1620-1621.

87. Dai C, Sun MJ, Jiang M. Level of Fecal Calprotectin and the Severity of Small Bowel Crohn's Disease. Clin Gastroenterol Hepatol 2017;15:320-321.

88. Dai C, Jiang M, Sun MJ. Rifaximin in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 2017;152:1629-1630.

89. Dai C, Jiang M, Sun MJ. The Risk of Gallstone Disease Following Colectomy for Ulcerative Colitis. Am J Gastroenterol 2017;112:1165.

90. Dai C, Jiang M, Sun MJ. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017;377:496.

91. Dai C, Cao Q, Jiang M. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients. J Clin Gastroenterol 2017.

92. Dai C, Cao Q, Jiang M. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017.

93. Dai C, Jiang M, Sun MJ. The Impact of Smoking on Inflammatory Bowel Disease. J Clin Gastroenterol 2016;50:93-4.

94. Dai C, Jiang M, Sun MJ. Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn's Disease. Inflamm Bowel Dis 2016;22:E3.

95. Dai C, Jiang M, Sun MJ. Mucosal Healing in the Treatment of Ulcerative Colitis: A Reliable Target? Clin Gastroenterol Hepatol 2016;14:1361.

96. Dai C, Jiang M, Sun MJ. Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 2016;43:1346.

97. Dai C, Jiang M, Sun MJ. Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2016;44:308-9.

98. Dai C, Jiang M, Sun MJ. Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease. Am J Gastroenterol 2016;111:1207.

99. Dai C, Jiang M, Sun MJ. The Symptoms Related to Irritable Bowel Syndrome and Organic Disease. J Clin Gastroenterol 2016;50:898-899.

100. Dai C, Jiang M, Sun MJ. Mesalamine in Recurrent Acute Colonic Diverticulitis. Am J Gastroenterol 2016;111:1656-1657.

101. Dai C, Jiang M, Sun MJ. Mesalazine in the Treatment of Symptomatic Uncomplicated Diverticular Disease. J Clin Gastroenterol 2016.

102. Dai C, Jiang M, Sun MJ. Statins and the Risk of Inflammatory Bowel Disease. Am J Gastroenterol 2016;111:1851.

103. Dai C, Jiang M, Sun MJ. Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease. J Crohns Colitis 2016.

104. Dai C, Liu WX, Jiang M, et al. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. World J Gastroenterol 2015;21:2534-41.

105. Dai C, Jiang M, Sun MJ. Fecal microbiota transplantation for treatment of Clostridium difficile infection. J Clin Gastroenterol 2015;49:171-2.

106. Dai C, Jiang M, Sun MJ. Letter: irritable bowel syndrome is significantly associated with somatisation. Aliment Pharmacol Ther 2015;41:791.

107. Dai C, Jiang M, Sun MJ. Innate immunity and adaptive immunity in Crohn's disease. Ann Transl Med 2015;3:34.

108. Dai C, Jiang M, Sun MJ. Can fecal calprotection identify postoperative recurrence of Crohn's disease? Inflamm Bowel Dis 2015;21:E7.

109. Dai C, Jiang M, Sun MJ. Can fecal microbial transplant effectively treat Crohn's disease? Inflamm Bowel Dis 2015;21:E8.

110. Dai C, Jiang M, Sun MJ. Fecal Calprotectin as a Predictor of Relapse in Patients With Inflammatory Bowel Disease. J Clin Gastroenterol 2015;49:715.

111. Dai C, Jiang M, Sun MJ. Treatment for Clostridium difficile infection in adults. JAMA 2015;313:1975-6.

112. Dai C, Jiang M, Sun MJ. Levels of fecal calprotectin and the severity of postoperative patients with Crohn's disease. Am J Gastroenterol 2015;110:1241-2.

113. Dai C, Jiang M, Sun MJ. The utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:1242-3.

114. Dai C, Liu WX, Jiang M, et al. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One 2014;9:e110797.

115. Dai C, Jiang M, Sun MJ. Letter: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:857-8.

116. Dai C, Jiang M, Sun MJ. Isotretinoin and risk of inflammatory bowel disease. Am J Gastroenterol 2014;109:1493-4.

117. Dai C, Jiang M, Sun MJ. The safety of probiotics in IBS and CIC is worthy of further discussion. Am J Gastroenterol 2014;109:1838-9.

118. Dai C, Zheng CQ, Meng FJ, et al. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-kappaB pathway in rat model of DSS-induced colitis. Mol Cell Biochem 2013;374:1-11.

119. Dai C, Zheng CQ, Jiang M, et al. Probiotics and irritable bowel syndrome. World J Gastroenterol 2013;19:5973-80.

120. Dai C, Zheng CQ, Jiang M. Letter: serotonin transporter gene polymorphisms and the irritable bowel syndrome. Aliment Pharmacol Ther 2013;37:657-8.

121. Dai C, Zheng CQ, Jiang M. Efficacy of probiotics in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:814-5.

122. Sang LX, Chang B, Dai C, Gao N, Liu WX, Jiang M. Heat-killed VSL#3 ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in rats. Int J Mol Sci. 2013;15(1):15-28.

123. Dai C, Zhao DH, Jiang M. VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways. Int J Mol Med 2012;29:202-8.

124. Dai C, Jiang M. The incidence and risk factors of post-infectious irritable bowel syndrome: a meta-analysis. Hepatogastroenterology 2012;59:67-72.

125. Dai C, Guandalini S, Zhao DH, et al. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol Cell Biochem 2012;362:43-53.

“辽宁省百千万人才工程”千人层次

沈阳市“拔尖人才”